Search clinical trials for: SHR-1819

Total 1884 results

Atridia Pty Ltd.

Completed

A Trial of SHR-1819 in Healthy Subjects

Healthy Volunteers

Australia
Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects

Asthma

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Moderate to Severe Atopic Dermatitis
Beijing Suncadia Pharmaceuticals Co., Ltd

Not yet recruiting

Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects

Diabetes
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy

Australia
Sanjay Gandhi Postgraduate Institute of Medical...
Ram Manohar Lohia Institute of Medical Sciences, Lucknow

Terminated

Re-treatment of HCV Following DAA Failure

Chronic Hepatitis C

India
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Coherent Biopharma (Hefei) Co., Ltd.

Recruiting

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Cancer, Breast | Cancer of Pancreas | Cancer Colorectal | Cancer, Lung | Cancer of Esophagus

China, United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

T2DM

China
Atridia Pty Ltd.

Active, not recruiting

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

Australia
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Eosinophilic Granulomatosis With Polyangiitis

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety and Tolerability of SHR-1918 in Healthy Subjects

Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer

ER Positive/HER2 Low Breast Cancer

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject

IgA Nephropathy

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects

Prevention of Arterial and Venous Thrombosis

China
University of California, Irvine

Completed

Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction

Hypertrichosis

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Gynaecological Malignancies

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Advanced Solid Tumours
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Advanced Solid Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Pharmacokinetic
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Recruiting

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

Hyperlipidemic

China
Hinova Pharmaceuticals USA, Inc.

Active, not recruiting

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Germany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
Symbiomix Therapeutics

Completed

A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

Bacterial Vaginosis

United States
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Phase I Study of SHR -2001 in Healthy Subjects

Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Advanced Solid Tumor

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Completed

A Trial of SHR - 1906 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

China

3

Subscribe